KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Capital Leases: 2023-2025

Historic Capital Leases for Castle Biosciences (CSTL) over the last 2 years, with Sep 2025 value amounting to $339,000.

  • Castle Biosciences' Capital Leases rose 17.30% to $339,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $339,000, marking a year-over-year increase of 17.30%. This contributed to the annual value of $311,000 for FY2024, which is 1144.00% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Capital Leases is $339,000, which was down 6.87% from $364,000 recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Capital Leases registered a high of $364,000 during Q2 2025, and its lowest value of $25,000 during Q4 2023.
  • Its 3-year average for Capital Leases is $281,143, with a median of $312,000 in 2024.
  • Data for Castle Biosciences' Capital Leases shows a peak YoY surged of 1,144.00% (in 2024) over the last 5 years.
  • Castle Biosciences' Capital Leases (Quarterly) stood at $25,000 in 2023, then soared by 1,144.00% to $311,000 in 2024, then increased by 17.30% to $339,000 in 2025.
  • Its Capital Leases was $339,000 in Q3 2025, compared to $364,000 in Q2 2025 and $328,000 in Q1 2025.